Pair page
ARA-290 with NAD+
Mechanism-tag overlap and published literature for ARA-290 and NAD+, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
epo-derivedinnate-repair-receptor-agonist
coenzymemitochondrial-longevity
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying ARA-290 and NAD+ have published these mechanism-level observations. Not a co-administration recommendation.
Mitochondrial support via NAD+ precursors complements ARA-290's IRR-mediated anti-apoptotic neuroprotection. Rationale is mechanistic — NAD+ supports the metabolic health of the same tissues ARA-290 protects.
Quick facts
ARA-290
NAD+
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2020 | ARA-290 | Brines M, Dunne A, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. Cibinetide (ARA 290) for treatment of sarcoidosis-associated chronic neuropathic pain: A randomized, double-blind, placebo-controlled study. Clin Immunol. 2020;… PMID 31982580 | human trial, Phase 2 |
| 2015 | ARA-290 | Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Kirk RI, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol… PMID 25387363 | human trial, Phase 2 |
| 2013 | ARA-290 | Dahan A, Dunne A, Swartjes M, Proto PL, Heij L, Vogels O, van Velzen M, Sarton E, Niesters M, Tannemaat MR, Cerami A, Brines M. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013;19:33… PMID 24100673 | human trial, Phase 2 |
| 2012 | ARA-290 | Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A, Grutters JC, Vogels O, Brines M, Cerami A, Dahan A. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(1):1430-1436.… PMID 23168581 | human trial |
| 2019 | ARA-290 | Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson CG, Petropoulos IN, Javed S, Malik RA, Cerami A, Dahan A. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 2019;60(2):5… | human study |
| 2017 | ARA-290 | Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts LPHJ, Tavee J, Tannemaat MR, Dunne AN, Kirk RI, Petropoulos IN, Cerami A, Malik RA, Brines M. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and ne… PMID 28475703 | human study |
| 2011 | ARA-290 | Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice. Anesthesiology. 201… PMID 21966093 | preclinical, in vivo |
| 2012 | ARA-290 | Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med. 2012;18(1):486-496. PMID: 22183892. (Key mechanistic review of the Innate Repair Receptor.) PMID 22183892 | review |
| — | ARA-290 | ClinicalTrials.gov. Search: "cibinetide" / "ARA-290" / "ARA 290". Multiple NCT records across sarcoidosis, diabetic neuropathy, chronic pain, renal protection, islet transplantation. | regulatory / registry |
| 2016 | ARA-290 | Watanabe M, Lundgren T, Saito Y, Cerami A, Brines M, Östenson CG, Bränström R. A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets. Transplantation. 2016;100(3):554-562. PMID: 26840669. PMID 26840669 | research article |
| 2016 | ARA-290 | Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the Innate Repair Receptor to Treat Neuropathy. Pain Rep. 2016;1(1):e566. PMID: 29392186. PMID 29392186 | research article |
| 2015 | ARA-290 | Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015;151:32-40. PMID: 25783068. PMID 25783068 | research article |
| 2015 | NAD+ | Chen AC, Martin AJ, Choy B, Fernández-Peñas P, Dalziell RA, McKenzie CA, Scolyer RA, Dhillon HM, Vardy JL, Kricker A, St George G, Chinniah N, Halliday GM, Damian DL. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015;373(17):1618-1626… PMID 26488693 | human trial, Phase 3 |
| 2023 | NAD+ | Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep. 20… PMID 36797283 | human trial |
| 2018 | NAD+ | Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effect… PMID 30084900 | human trial |
| 2017 | NAD+ | Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D, Tian R, Shen DD, O'Brien KD. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy voluntee… PMID 29211728 | human trial |
| 2022 | NAD+ | Brakedal B, Dölle C, Riemer F, Ma Y, Nido GS, Skeie GO, Craven AR, Schwarzlmüller T, Brekke N, Diab J, Sverkeli L, Skjeie V, Varhaug K, Tysnes OB, Peng S, Haugarvoll K, Ziegler M, Grüner R, Eidelberg D, Tzoulis C. The NADPARK study: A randomized phase I trial of nicotinamide rib… PMID 35537443 | human trial, Phase 1 |
| 2019 | NAD+ | Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257. PMID: 31572171. PMID 31572171 | human pilot |
| 2018 | NAD+ | Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, Chonchol M, Seals DR. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478. PMID 29599478 | human study |
| 2023 | NAD+ | Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, Kapogiannis D, Martens CR. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754. PM… PMID 36448627 | research article |
| 2022 | NAD+ | Freeberg KA, Craighead DH, Martens CR, You Z, Chonchol M, Seals DR. Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Front Cardiovasc Med. 2022;9:881703. PMID: 35757350. PMID 35757350 | research article |
| 2021 | NAD+ | Yoshino M, Yoshino J, Kayser BD, Patti GJ, Franczyk MP, Mills KF, Sindelar M, Pietka T, Patterson BW, Imai SI, Klein S. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596. PMID 33888596 | research article |
| 2019 | NAD+ | Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG. Nicotinamide Riboside A… PMID 31390667 | research article |
| 2018 | NAD+ | Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513-528. PMID: 29249689. PMID 29249689 | research article |
Related pair pages
More research context
Frequently asked
Have ARA-290 and NAD+ been studied together?
Researchers have published mechanistic-level co-administration discussion of ARA-290 and NAD+. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do ARA-290 and NAD+ share?
ARA-290 and NAD+ do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of ARA-290 and NAD+?
ARA-290: Not approved (orphan designation for sarcoidosis). NAD+: Not approved (IV off-label). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on ARA-290 and NAD+?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the ARA-290 profile and the NAD+ profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026